CLASS II Drug recall · Reported 6 Nov 2019 · FDA Enforcement Report

Ranitidine Hydrochloride Capsules 150 mg recalled by AVKARE

AVKARE is recalling Avkare Ranitidine Hydrochloride Capsules 150 mg, distributed in Colorado, Missouri. The recall was initiated on 17 Oct 2019 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot 17708 Exp.11/30/2019 Lot 18459 Exp.03/31/2020 Lot 19033 Exp.07/31/2020 Lot 19032 Exp.07/31/2020 Lot 19031 Exp.06/30/2020 Lot 20204 Exp.09/30/2020 Lot 20205 Exp.09/30/2020 Lot 20663 Exp.10/31/2020 Lot 20664 Exp.11/30/2020 Lot 20665 Exp.11/30/2020 Lot 20666 Exp.11/30/2020 Lot 21039 Exp.12/31/2020 Lot 21920 Exp.04/30/2021
Quantity recalled7293 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0164-2020
FDA event ID
84081
Recalling firm
AVKARE, Pulaski, TN
Classification
Class II
Status
Terminated
Recall initiated
17 Oct 2019
FDA classified
28 Oct 2019
Reported
6 Nov 2019
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity

Timeline

17 Oct 2019Recall initiated by company
28 Oct 2019Classified by FDA+11 days
6 Nov 2019Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

AVKARE Ranitidine Hydrochloride Capsules 150 mg 500 Capsules Rx Only NDC 42291-735-50 UPC 342291735507 Manufactured for: AvKARE, Inc. Pulaski, TN 38478

Where it was distributed

CO, MO

ColoradoMissouri

Questions about this recall

Is Ranitidine Hydrochloride Capsules 150 mg recalled?

Yes. AVKARE recalled Ranitidine Hydrochloride Capsules 150 mg on 17 Oct 2019. The recall is Class II and its status is Terminated. Recall number D-0164-2020.

Why was it recalled?

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Which lots are affected?

Lot 17708 Exp.11/30/2019 Lot 18459 Exp.03/31/2020 Lot 19033 Exp.07/31/2020 Lot 19032 Exp.07/31/2020 Lot 19031 Exp.06/30/2020 Lot 20204 Exp.09/30/2020 Lot 20205 Exp.09/30/2020 Lot 20663 Exp.10/31/2020 Lot 20664 Exp.11/30/2020 Lot 20665 Exp.11/30/2020 Lot 20666 Exp.11/30/2020 Lot 21039 Exp.12/31/2020 Lot 21920 Exp.04/30/2021

Where was it sold?

CO, MO

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from AVKARE

All 57
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIAmantadine HCl, Capsules, UPS, 100 mg dose recalled by AvKAREAmantadine HclAvKAREPotency & AssayNationwide
DrugCLASS IIRosuvastatin Tablets, USP, 10 mg recalled by AvKARERosuvastatinAvKAREPotency & AssayNationwide
DrugCLASS IINorgestimate and Ethinyl Estradiol Tablets recalled by AvKARENorgestimate And Ethinyl EstradiolAvKAREOtherNationwide
DrugCLASS IIchloroproMAZINE Hydrochloride Tablets, USP, 100 mg unit dose recalledChlorpromazine HydrochlorideAvKAREOtherNationwide
DrugCLASS IIchloroproMAZINE Hydrochloride Tablets, USP, 50 mg unit dose recalledChlorpromazine HydrochlorideAvKAREOtherNationwide

Other Avkare ranitidine recalls

All 4